We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRBW
276
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$47K ﹤0.01%
+65,362
New +$198K
CYTR
277
CALL
DELISTED
CytRx Corp
CYTR
$46K ﹤0.01%
28
– –
ADYX
278
CALL
DELISTED
Adynxx Inc
ADYX
$40K ﹤0.01%
+8
New +$640
TNXP icon
279
CALL
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
TENX icon
280
CALL
Tenax Therapeutics
TENX
$385M
– –
0
– –
ATRS
281
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$35K ﹤0.01%
399
-467
-54% -$452
RXII
282
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$34K ﹤0.01%
235
-6,607
-97% -$956K
IMNN icon
283
Imunon
IMNN
$6.35M
$27K ﹤0.01%
7
– –
IPCI
284
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$25K ﹤0.01%
12
-5
-29% -$111
RNVA
285
DELISTED
Rennova Health, Inc.
RNVA
$23K ﹤0.01%
68
+1
+1% +$367
OPXAW
286
DELISTED
Opexa Therapeutics, Inc.
OPXAW
$2K ﹤0.01%
+34,097
New +$2.42K
AAPL icon
287
CALL
Apple
AAPL
$4.89T
– –
-4,440
Closed -$11.7M
AAPL icon
288
PUT
Apple
AAPL
$4.89T
– –
-4,736
Closed -$12.5M
ABBV icon
289
AbbVie
ABBV
$458B
– –
-46,166
Closed -$2.57M
AFMD
290
DELISTED
Affimed
AFMD
– –
-5,677
Closed -$404K
ALKS icon
291
CALL
Alkermes
ALKS
$8.82B
– –
-568
Closed -$4.51M
ALKS icon
292
PUT
Alkermes
ALKS
$8.82B
– –
-3,156
Closed -$25.1M
ASRT
293
PUT
DELISTED
Assertio
ASRT
– –
-4
Closed -$408K
AVDL
294
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-12,100
Closed -$148K
AVDL
295
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-190
Closed -$232K
BCRX icon
296
BioCryst Pharmaceuticals
BCRX
$2.37B
– –
-165,529
Closed -$1.71M
BCRX icon
297
PUT
BioCryst Pharmaceuticals
BCRX
$2.37B
– –
-1,937
Closed -$2M
BLUE
298
CALL
DELISTED
bluebird bio
BLUE
– –
-66
Closed -$5.53M
BLUE
299
DELISTED
bluebird bio
BLUE
– –
-3,509
Closed -$2.92M
BLUE
300
PUT
DELISTED
bluebird bio
BLUE
– –
-40
Closed -$3.31M
10 11
12
13 14

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.